Clinical trials: Type2Diabetes
Diabete Mellitus, Type2diabetes
CGM Experience, Preferences & Blood Glucose Parameters
This is an open-label, prospective, multicenter observational study designed to evaluate the perceived benefits, device experience, preference, and glucose-related parameters associated with the Instara-1 Continuous Glucose…
- Conditions
- Diabete Mellitus, Type2diabetes, type1diabetes, Gestational Diabetes
- Trial name
- NCT07607015
- Testing
- CGM
- Volunteers
- 75 people
- Sponsor
- Getz Pharma
Type2diabetes, Endothelial Dysfunction
A Trial to Evaluate the Effect of C21 on Endothelial Dysfunction in Subjects With Type 2 Diabetes
This trial is a single-centre, randomized, double-blind, placebo-controlled, 2-way cross-over phase 1b trial evaluating the pharmacodynamic effect of C21 on endothelial dysfunction and safety in subjects with type 2 diabetes…
- Trial name
- NCT05831644
- Testing
- C21
- Where
- Sweden
- Volunteers
- 11 people
- Sponsor
- Vicore Pharma AB
Type2diabetes
A Post-Marketing Safety Study of Dorzagliatin in Patients With Type 2 Diabetes
The primary objective of this study is to evaluate the long-term safety of Dorzagliatin in a larger population of type 2 diabetes mellitus patients by collecting the post-marketing clinical safety data of Dorzagliatin.
- Trial name
- BLOOM (NCT06263348)
- Testing
- Dorzagliatin tablets
- Where
- China
- Volunteers
- 2,024 people
- Sponsor
- Hua Medicine Limited
Type2diabetes
The Attractive 2 Trial - Pharmacokinetics of ATR-258 Oral Capsule vs. Oral Solution Formulations in Healthy Volunteers
This is a single-centre, open-label, randomised, 2-period cross-over, Phase 1 comparative trial to assess the ATR-258 pharmacokinetic (PK) parameters of an oral capsule formulation in comparison with an oral solution formulation…
- Trial name
- Attractive 2 (NCT06432673)
- Testing
- ATR-258 Oral solution, ATR-258 Oral capsule
- Where
- Sweden
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Atrogi AB
Type2Diabetes
A Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393(2) in Healthy Volunteers Under Fed Conditions
A Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393(2) in Healthy Volunteers Under Fed Conditions
- Trial name
- NCT05347576
- Testing
- CKD-393(2), CKD-501, D759, D150, D029
- Where
- South Korea
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Type 2 Diabetes Mellitus, Type2diabetes
Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes
This study is designed to evaluate the safety and effectiveness of endoscopic intestinal re-cellularization therapy in individuals with type 2 diabetes (T2D) inadequately controlled on non-insulin glucose-lowering medications.
- Conditions
- Type 2 Diabetes Mellitus, Type2diabetes, Diabetes Mellitus, Type 2, Diabetes
- Trial name
- NCT06267391
- Testing
- Endogenex Treatment
- Where
- 44 sites in United States, Australia
- Volunteers
- 350 people
- Sponsor
- Endogenex, Inc.
Type2diabetes
Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants
This is a Phase 1b, randomized, open-label, active-controlled, parallel, multiple-dose study comparing the safety, pharmacokinetics and efficacy of DehydraTECH Cannabidiol and Glucagon-like Peptide 1 (GLP-1) agonists alone and in…
- Trial name
- DehydraTECH (NCT06648031)
- Testing
- Arm 1 - DehydraTECH-CBD alone, Arm 2 - DehydraTECH-semaglutide alone, Arm 3 - DehydraTECH-CBD in combination with DehydraTECH-semaglutide
- Where
- 7 sites in Australia
- Volunteers
- 148 people
- Sponsor
- Lexaria Bioscience Corp.
Type 1 Diabetes, Type2diabetes
Liom Non-invasive Continuous Glucose Monitor "Clinical Demo" (niCGM)
This is a single-centre, multiple cohort, open study.
- Trial name
- NCT06272136
- Testing
- Clinical Demo 2.0
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- Liom Health AG
Type 2 Diabetes Mellitus in Obese, Obesity
A Study to Assess 11 Beta-hydroxysteroid Dehydrogenase Type 1 Inhibition in Adipose Tissue by SPI-62
This will be an exploratory, open-label study of 11β-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibition by SPI-62 in obese subjects with type 2 diabetes mellitus (T2DM)
- Conditions
- Type 2 Diabetes Mellitus in Obese, Obesity, Type2Diabetes
- Trial name
- NCT05409027
- Testing
- SPI-62, Cortisone-d8
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Sparrow Pharmaceuticals
Type2diabetes, Rheumatoid Arthritis
Understanding Ayurveda Disease Conditions and Treatment Responses
The goal of this observational study is to assess Prakriti \& Vikriti in patients visiting OPD of IIISM department, SRM hospital.
- Conditions
- Type2diabetes, Rheumatoid Arthritis, Osteo Arthritis Knee, Skin Diseases
- Trial name
- NCT06167226
- Testing
- Personalized Ayurveda treatment protocol
- Where
- India
- Volunteers
- 497 people
- Sponsor
- Ayurai Private Limited
Type 2 Diabetes Mellitus (T2DM), Type2Diabetes
Post-market SUrveiLlance RegiStry for the Endogenex System (Endogenex PULSE Registry)
This registry is designed to collect long-term data and support ongoing post-market surveillance of real-world data for the Endogenex System.
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Type2Diabetes, Diabetes Mellitus, Type 2, Type 2 Diabetes
- Trial name
- NCT07197775
- Where
- 4 sites in United States, Australia
- Volunteers
- 500 people
- Sponsor
- Endogenex, Inc.
Diabetes Mellitus, Type 2, Diabetes
Evaluation of Fuling Yunhua Granules and Dihuang Baoyuan Granules in Drug Naive Type 2 Diabetes Patients
The goal of this investigator-initiated clinical trial is to investigate the efficacy and safety of sequential therapy of Fuling Yunhua Granules (prescription A) and Dihuang Baoyuan Granule (prescription B) in the treatment of…
- Conditions
- Diabetes Mellitus, Type 2, Diabetes, Type2diabetes
- Trial name
- NCT06575478
- Testing
- Fuling Yunhua Granules, Dihuang Baoyuan Granules
- Where
- China
- Volunteers
- 95 people
- Sponsor
- Beijing Supreme Life Pharmaceutical Technology Co., Ltd.
Type 2 Diabetes Mellitus, Type2diabetes
Continued Access to the Endogenex System for Participants in the ReCET Pivotal Study
This study is designed to collect real-world data on the safety and performance of the Endogenex System in the cohort of participants who were originally randomized to the sham control arm of the ReCET Study.
- Conditions
- Type 2 Diabetes Mellitus, Type2diabetes, Diabetes Mellitus, Type 2, Type 2 Diabetes
- Trial name
- NCT07197788
- Testing
- Endogenex System
- Where
- 11 sites in United States, Australia
- Volunteers
- 50 people
- Sponsor
- Endogenex, Inc.
Type2diabetes
Bioequivalence Study to Compare Empagliflozin/ Metformin HCl 12.5mg/1000mg Film-coated Tablets
Randomized, two-way, two-period, single oral dose, open-label, crossover, bioequivalence study to compare Empagliflozin/ Metformin HCl 12.5mg/1000mg film-coated tablets (12.5mg Empagliflozin / 1000mg Metformin HCl) versus…
- Trial name
- NCT06450262
- Testing
- Emapgliflozin/Metformin 12.5mg/1000mg Film-coated tablets, Synjardy® 12.5mg/1000mg film-coated tablets
- Where
- Jordan
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Type2diabetes
DM Treatment to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone in Patients with Type 2 Diabetes
Key finding of DM Treatment with combination, A MuLticenter, Randomized, Parallel, Gathering Information of phase 4 Trial to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone add-on to Metformin and DPP-4…
- Trial name
- KLIMT (NCT06875193)
- Testing
- DW6012(Dasidiem tab. 10/100mg)
- Where
- South Korea
- Volunteers
- 196 people
- Sponsor
- Dong Wha Pharmaceutical Co. Ltd.
Overweight and Obesity, Type2diabetes
Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant
The purpose of this study is to evaluate the safety, tolerability and drug levels of an exenatide implant administered subcutaneously.
- Trial name
- LIBERATE-1 (NCT05670379)
- Testing
- Exenatide Implant, Bydureon BCise (exenatide extended release), Semaglutide, 1.0 mg/mL
- Where
- Australia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Vivani Medical, Inc